The startup develops therapeutics that utilize microbiome-derived compounds to create oral treatments for type 1 diabetes and other metabolic diseases. By focusing on autoimmune disorders, the company aims to provide effective alternatives to current injectable therapies, enhancing patient compliance and treatment outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for type 1 diabetes (T1D) and other autoimmune diseases often involve injectable therapies, which can lead to patient non-compliance and suboptimal treatment outcomes. These conditions, characterized by the body's immune system attacking its own tissues, affect millions worldwide and require chronic management.
Solution
AMI Pharma is developing a single, daily oral dose therapeutic for type 1 diabetes and other autoimmune diseases, utilizing microbiome-derived compounds. By focusing on oral administration, AMI Pharma aims to provide a more convenient and patient-friendly alternative to existing injectable treatments. The company's approach leverages patented discoveries related to microbiome development to modulate the immune system and address the underlying causes of autoimmune disorders. This aims to improve patient adherence and ultimately enhance the effectiveness of treatment for these chronic conditions.
Target Audience
The primary target audience includes individuals with type 1 diabetes and other autoimmune diseases, as well as healthcare providers specializing in endocrinology, immunology, and related fields.
Features
- Utilizes purified microbiome-based strains, metabolites, and related compounds.
- Focuses on oral administration for improved patient compliance.
- Targets the underlying causes of autoimmune disorders through microbiome modulation.
- Development pipeline includes treatments for Type 1 Diabetes (T1D) and other Auto-Immune Diseases (AIDs).